
Loading, please wait...

Loading, please wait...

Experts analyzed 2,098 patients with early-stage ER+ HER2− invasive lobular carcinoma (ILC) to examine the prevalence and prognostic relevance of HER2-low status. HER2-low tumors were found in 52.6% of patients and were associated with larger tumor size and multifocality. Compared to HER2 0, HER2-low status was independently associated with worse disease-free survival and overall survival, but not with distant recurrence-free survival.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


Experts analyzed 2,098 patients with early-stage ER+ HER2− invasive lobular carcinoma (ILC) to examine the prevalence and prognostic relevance of HER2-low status. HER2-low tumors were found in 52.6% of patients and were associated with larger tumor size and multifocality. Compared to HER2 0, HER2-low status was independently associated with worse disease-free survival and overall survival, but not with distant recurrence-free survival.
2 months ago

Co-administering antiseizure medications and DOACs frequently causes pharmacokinetic interactions, subtherapeutic drug levels, and thromboembolic failures. This review highlights enzyme induction risks, unpredictable outcomes with levetiracetam, and the vital role of therapeutic drug monitoring.
Today

Demanding exhaustive hormonal profiling can inadvertently discourage clinical studies involving females. Methodological standards must align with the specific scientific question to expand, not restrict, equitable evidence for women.
Today

An elderly man with partially repaired Tetralogy of Fallot presented with STEMI caused by coronary embolism rather than atherosclerosis. Successful treatment with sustained mechanical aspiration thrombectomy underscores the vital need for high clinical vigilance in adult congenital heart disease.
Today

A comparative review of tension band wiring and intramedullary screw fixation in thumb metacarpophalangeal arthrodesis, evaluating union rates, hardware complications, and clinical outcomes.
Today

Following regulatory scrutiny from FSSAI regarding promotional representations and lean muscle preservation claims, Dr. Reddy's Laboratories and Nestlé Health Science are currently reviewing the branding and marketing strategy for their joint nutritional supplement Celevida GLP+.
Today